Morgan Stanley on Eli Lilly (LLY): retatrutide weight loss data 'encouraging,' but offset by GI adverse events
Tweet Send to a Friend
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,313.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
